-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2023-504554-35-00
5
2025-01-17
incisional hernia
-
2024-516372-14-00
11
2025-01-13
Asymptomatic Patients with frequent PVCs and normal LVEF
-
2023-508794-83-00
4
2025-01-10
Epidermolysis bullosa simplex
-
2023-509811-98-00
4
2025-01-07
Patients with HER2-positive locally advanced inoperable or metastatic
-
2023-506350-21-00
4
2025-01-06
Localized, resected, FIGO stage I (2018 classification), uterine leiom
-
2023-507633-21-01
5
2024-12-09
Multiple Sclerosis
-
2024-516109-21-00
5
2024-12-09
Polycythaemia Vera (PV)
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2023-508400-38-00
4
2024-11-29
meningioma
-
2023-508949-40-00
4
2024-11-29
Eosinophilic esophagitis
-
2024-517408-12-00
5
2024-11-28
Patient in end-stage renal disease candidate for a kidney transplant
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2024-515219-23-00
3
2024-11-08
multiple myeloma
-
2024-514886-21-00
6
2024-11-06
Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus
(P
-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-504755-26-00
4
2024-10-21
Bronchiectasis
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2024-516782-36-00
4
2024-10-15
metastatic or recurrent endometrial or ovarian carcinosarcoma
-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional